Form 8-K Adicet Bio, Inc. For: Aug 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
BTIG Reiterates Buy Rating on Adicet Bio Inc. (ACET)
August 14, 2024 6:11 AM EDTBTIG analyst Justin Zelin reiterated a Buy rating and $6.00 price target on Adicet Bio Inc. (NASDAQ: ACET).
The analyst comments "Adicet reported 2Q24 earnings, with expansion of ADI-001 autoimmune clinical development beyond lupus nephritis to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil... More
